Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Breeze Meds

Two GLP-1 desks, one scoreboard. We put HealthRX and Breeze Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 37 · Grade C

Breeze Meds

Visit Breeze Meds Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 76 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Breeze Meds a bad call — it's best for readers starting at a low dose who want nothing charged until a provider has approved them. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
70
Supply Reliability
85
82
Transparency
83
60
Access Breadth
91
88
Clinical Oversight
89
78
Track Record
81
76
HealthRXBrief Score 86 · 76Breeze Meds

Price, coverage & the tracker

HealthRXBreeze Meds
Brief Score86/100 (B)76/100 (C)
Semaglutide$189/moFrom $199/mo injectable · $299/mo oral (lowest dose)
Tirzepatide$349/moFrom $399/mo injectable · $399/mo oral (lowest dose)
CoverageNot publicly listedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Breeze Meds: ⚠ Every published figure is quoted at the LOWEST dose — the funnel says higher doses may cost more, so these are floors.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.